Tetra Bio Pharma Inc TBPMQ

Healthcare Cannabis

Tetra Bio-Pharma Inc. is a Canada-based cannabinoid-derived drug discovery and development company. The Company has developed a pipeline of cannabinoid-based drug products for a range of medical conditions, including pain, inflammation, and oncology. The Company has a pipeline of formulations and drug delivery systems with a portfolio of assets from the early research and development phase to advanced stage clinical programs. Its products include QIXLEEF, CAUMZ, PPP004, REDUVO, and REBORN 1. QIXLEEF is a botanical therapy with a fixed dosage of tetrahydrocannabinol (THC) and cannabidiol (CBD). CAUMZ is its inhaled cannabinoid-derived drug candidate. PPP004 is a topical preparation containing either a standardized amount of CBD or a defined ratio of THC and CBD. REDUVO is a soft gel capsule used to treat chemotherapy-induced nausea and vomiting (CINV) and weight loss and severe nausea in people living with human immunodeficiency virus (HIV) infection. REBORN 1 is in phase II trial.

GREY:TBPMQ - Post by User

Tetra Bio Pharma Inc > Pricing of Marketed Public Offering of Units

<< Previous

Bullboard Posts

Next >>

Post by Bangadaon Dec 14, 2021 6:06pm

218 Views

Post# 34230788

Pricing of Marketed Public Offering of Units

$0.163 per Unit for aggregate gross proceeds of up to $6.8 million. Warrants for $0.195 ~ 48 months....holy moly.
At least they are pleased to announce it...

<< Previous

Bullboard Posts

Next >>

Pro Women’s Hockey League comes to NHL 25 in December